Macquarie Group’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,323,547
| Closed | -$9.78M | – | 1761 |
|
|
2022
Q4 | $9.78M | Sell |
1,323,547
-1,604,995
| -55% | -$15.6M | 0.01% | 839 |
|
|
2022
Q3 | $28.9M | Buy |
2,928,542
+50,962
| +2% | +$538K | 0.04% | 587 |
|
|
2022
Q2 | $31.4M | Sell |
2,877,580
-50,898
| -2% | -$527K | 0.04% | 596 |
|
|
2022
Q1 | $33.1K | Buy |
2,928,478
+15,007
| +0.5% | +$197K | 0.03% | 642 |
|
|
2021
Q4 | $45.7M | Sell |
2,913,471
-323,053
| -10% | -$5.63M | 0.04% | 539 |
|
|
2021
Q3 | $55.5M | Buy |
3,236,524
+31,688
| +1% | +$555K | 0.05% | 485 |
|
|
2021
Q2 | $68.9M | Buy |
3,204,836
+57,958
| +2% | +$1.04M | 0.06% | 424 |
|
|
2021
Q1 | $47.3M | Sell |
3,146,878
-45,156
| -1% | -$731K | 0.07% | 346 |
|
|
2020
Q4 | $41.9M | Sell |
3,192,034
-95,989
| -3% | -$1.16M | 0.06% | 347 |
|
|
2020
Q3 | $31.8M | Sell |
3,288,023
-2,555
| -0.1% | -$27.3K | 0.05% | 363 |
|
|
2020
Q2 | $37.6M | Buy |
3,290,578
+89,615
| +3% | +$1.01M | 0.06% | 309 |
|
|
2020
Q1 | $33.2M | Buy |
3,200,963
+103,141
| +3% | +$1.28M | 0.07% | 302 |
|
|
2019
Q4 | $50.8M | Buy |
3,097,822
+307,226
| +11% | +$4.64M | 0.07% | 293 |
|
|
2019
Q3 | $37.1M | Buy |
2,790,596
+185,904
| +7% | +$2.59M | 0.06% | 320 |
|
|
2019
Q2 | $36.7M | Buy |
2,604,692
+247,850
| +11% | +$3.94M | 0.06% | 324 |
|
|
2019
Q1 | $43.4M | Sell |
2,356,842
-101,442
| -4% | -$2.31M | 0.07% | 281 |
|
|
2018
Q4 | $64.2M | Sell |
2,458,284
-222,860
| -8% | -$5.24M | 0.12% | 148 |
|
|
2018
Q3 | $61.5M | Buy |
2,681,144
+126,140
| +5% | +$2.58M | 0.1% | 209 |
|
|
2018
Q2 | $48.7M | Buy |
2,555,004
+276,057
| +12% | +$4.62M | 0.08% | 247 |
|
|
2018
Q1 | $38.4M | Buy |
2,278,947
+10,256
| +0.5% | +$172K | 0.07% | 297 |
|
|
2017
Q4 | $34.5M | Buy |
2,268,691
+378,606
| +20% | +$5.62M | 0.06% | 327 |
|
|
2017
Q3 | $33.8M | Buy |
1,890,085
+186,526
| +11% | +$3.12M | 0.06% | 325 |
|
|
2017
Q2 | $27.8M | Buy |
1,703,559
+138,278
| +9% | +$1.99M | 0.05% | 364 |
|
|
2017
Q1 | $21.9M | Buy |
1,565,281
+192,641
| +14% | +$2.75M | 0.04% | 438 |
|
|
2016
Q4 | $21.9M | Buy |
1,372,640
+86,891
| +7% | +$1.4M | 0.04% | 407 |
|
|
2016
Q3 | $21.4M | Sell |
1,285,749
-1,779,317
| -58% | -$24M | 0.04% | 393 |
|
|
2016
Q2 | $34.3M | Buy |
3,065,066
+1,835,124
| +149% | +$17.8M | 0.03% | 422 |
|
|
2016
Q1 | $10.3M | Buy |
1,229,942
+140,410
| +13% | +$1.15M | 0.02% | 547 |
|
|
2015
Q4 | $10.1M | Buy |
1,089,532
+82,474
| +8% | +$823K | 0.02% | 538 |
|
|
2015
Q3 | $11.4M | Buy |
1,007,058
+192,487
| +24% | +$2.35M | 0.02% | 486 |
|
|
2015
Q2 | $10.3M | Buy |
814,571
+105,097
| +15% | +$1.13M | 0.02% | 537 |
|
|
2015
Q1 | $6.6M | Buy |
709,474
+579,474
| +446% | +$6.55M | 0.01% | 666 |
|
|
2014
Q4 | $1.86M | Hold |
130,000
| – | – | ﹤0.01% | 1035 |
|
|
2014
Q3 | $1.35M | Sell |
130,000
-50,000
| -28% | -$655K | ﹤0.01% | 1113 |
|
|
2014
Q2 | $2.91M | Sell |
180,000
-100,000
| -36% | -$1.33M | 0.01% | 906 |
|
|
2014
Q1 | $4.55M | Buy |
280,000
+143,000
| +104% | +$2.03M | 0.01% | 696 |
|
|
2013
Q4 | $1.7M | Buy |
+137,000
| New | +$1.38M | ﹤0.01% | 1045 |
|
Other funds holding VNDA
Macquarie Group's VNDA Position: Q1 2023 in Review
Macquarie Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 1,323,547 shares — an estimated $9.78M sold.
Macquarie Group first reported a position in VNDA in Q4 2013 and held it in 37 quarters. The position peaked at $68.9M in Q2 2021. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.
- Macquarie Group reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
- Macquarie Group sold 1,323,547 Vanda Pharmaceuticals shares in Q1 2023, an estimated $9.78M.
- Macquarie Group first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 37 quarters.
- Macquarie Group's Vanda Pharmaceuticals position peaked at $68.9M in Q2 2021.
- 177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.
Based on Macquarie Group's 13F filing for Q1 2023, filed 15 May 2023.